To read the full story, subscribe or sign in.

Alkermes launches phase I in MS with eye on Biogen's Tecfidera

July 18, 2014

Alkermes plc is ramping up a phase I study of ALKS-8700, a small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 22, 2025.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.